News and Comments

ILLUMINA AND THE FUTURE OF LIFE SCIENCES

  Wednesday, July 24, 2013

The moment some investors learned that ILLUMINA (ILMN) might acquire Advanced Liquid Logic (ALL), they debated selling the stock without knowing anything about the acquired firm or the advantages Illumina will add to its technological capability by acquiring it. Is this not the rule of thumb made possible by the power of computers’ programing? ILMN was already down anyway for the day, losing $0.95 during the bad NASDAQ day for the biotech sector in general. Long-term serious investors who are lured to sell ILMN must have felt bad when they heard the news after the end of Monday trading day.     More...

A GREAT DAY AND A GREAT FUTURE FOR ALNYLAM

  Thursday, July 11, 2013

A GREAT DAY AND A GREAT FUTURE FOR ALNYLAM  More...

UNREASONABLE CAUSE FOR SELLING CYTK

  Monday, July 08, 2013

The BENEFIT-ALS TRIALS: Cytokinetics (CYTK) announced an update on the conduct of BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS).  The BENEFIT-ALS is a Phase 2b, multinational, double-blind, randomized, placebo-controlled clinical trial designed to evaluate the safety, tolerability and potential efficacy of tirasemtiv, a fast skeletal muscle troponin activator, in patients with amyotrophic lateral sclerosis (ALS). More...

New Development in Amgen offer To Acquire Onyx

  Sunday, June 30, 2013

In a new development, Onyx (ONXX) confirmed Amgen’s offer in the same release that announced rejecting it. Indeed, Onyx has rejected Amgen’s unsolicited proposal that suggests acquiring Onyx’s outstanding shares and share equivalents for $120 per share in cash, subject to due diligence and other conditions.  More...

ONYX TAKEOVER WAS EXPECTED

  Sunday, June 30, 2013

In November 2011 Prohost posted an article titled “Deal or no deal, time for a payoff” (click HERE to read the article). All that prophesized in that article about Onyx’ (ONXX) drugs and prospects has materialized and the final item, a takeover, seems to be on the verge of happening.   More...

Two Small Great Biotechs Underestimated by the Market

  Tuesday, June 25, 2013

Seattle Genetics’ (SGEN) and ImmunoGen’s (IMGN) conjugated monoclonal antibody therapeutics for cancer are increasingly validating their superior safety and efficacy over other cancer products that are used without the antibody drug conjugates (ADC).  More...

Why Amgen and Cytokinetics Agreement is Good News?

  Wednesday, June 12, 2013

NEWS WE WERE WAITING FOR More...

THE REAL VALUE OF SEATTLE GENETICS

  Wednesday, May 08, 2013

 More...

SAREPTA: What's Going On ?

  Tuesday, April 16, 2013

The requests Sarepta Therapeutics (SRPT) has gotten from the FDA represent a sign of FDA seriousness towards bringing the firm’s drug eteplirsen for Duchenne muscular dystrophy as soon as possible to the children suffering from the debilitating, fast deteriorating disease. The FDA did not wait for the firm to file for early approval, it rather asked Sarepta to bring in more data that would legitimize granting early approval of the first drug ever to claim treating the disabling disease at its root-origin. Investors who should have been optimistic about the FDA initiative sold their shares instead, causing them to lose around 10% of their value.  More...

ImmunoGen Offers New Hopes For Treatment Of Subtypes Of Squamous Cell Carcinomas And Other Difficult-To-Treat Cancers

  Friday, April 12, 2013

 More...


Recent News_and_Comments


Archive


Tags